Deals channel feed – Endpoints News

Deals channel feed

In yet another delay for the F-star buyout, CFIUS extends review of 'national security risks'

3 years ago

Gilead's Kite nabs Carl June spinout Tmunity after neurotox kills patients, forcing reorg — and a rethink

3 years ago

Boehringer Ingelheim deepens its collaboration with Click Therapeutics in a deal worth $460M

3 years ago

Pfizer opts in to net LianBio’s rights to RSV candidate, putting down $20M upfront

3 years ago

Sanofi plucks three more NK cell engagers from French biotech partner, putting down €25M cash

3 years ago

Blackstone reconsiders future of Japanese pharma — report

3 years ago

Eli Lilly and Sosei enter into diabetes and metabolic disease deal, going after GPCR

3 years ago

Despite 'lackluster' 2022, PwC remains 'bullish' on pharma M&A in 2023

3 years ago

Scoop: Blade Therapeutics CEO, CFO appear to depart amid 'transition' after nixed SPAC

3 years ago

Novartis offloads five eye drugs in deal worth up to $175M

3 years ago

Prothena hopes to raise $180M after Eisai Alzheimer's data prompted stock surge

3 years ago

Say goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on Nasdaq

3 years ago

Corrected: AbbVie, Ipsen end partnerships with Exicure following setbacks, job cuts

3 years ago

In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront

3 years ago

Wave Life Sciences to receive $170M upfront in new partnership with GSK to develop a large number of candidates

3 years ago

Vertex, Moderna prepare to take their inhaled mRNA cystic fibrosis drug into the clinic

3 years ago

Clovis files for bankruptcy, will keep operating and plans to sell pipeline asset to Novartis

3 years ago

Updated: Horizon's $28B sale to Amgen was kicked off by Sanofi's interest

3 years ago

Updated: Amgen in advanced talks for Horizon, WSJ reports; Sanofi pulls out

3 years ago

Updated: Gilead, Arcellx team up on anti-BCMA CAR-T as biotech touts a 100% response rate at #ASH22

3 years ago

Erasca delves further into RAS/MAPK with Novartis drug, prices $100M offering

3 years ago

Sanofi walks away from $500M deal, leaving Revolution alone in pushing SHP2/KRAS combo

3 years ago

Vertex just found the next big ‘transformative’ thing for the pipeline — at a biotech just down the street

3 years ago

Sumitovant subsidiaries Enzyvant and Altavant merge into combined company

3 years ago

First page Previous page 44 45 464748 49 50 Next page Last page